Multisystem inflammatory syndrome in adults (MIS-A) is a new syndrome related with COVID-19 . A case-based review was performed to present real-life experiences in terms of main findings and treatment options . We described two cases with the diagnosis of MIS and searched the literature to review all reported ≥ 18-year-old cases . The PubMed, Scopus, and Web of Science databases were searched . All relevant articles from January 2020 to February 2021 were reviewed . An adolescent and an adult patient (18 and 40 years-old, respectively) with the diagnosis of MIS were presented . Both had the consistent clinical findings with the case definition criteria . Although steroid, intravenous immunoglobulin (IVIG) and supportive care treatments have been suggested in the literature, there exists no treatment guideline for MIS-A . The clinical and laboratory findings of the patients progressively improved with the implementation of the IVIG and the pulse steroid treatments . A total of 51 cases (≥ 18 years-old) with MIS were analyzed . Mean age was 29.4 ± 10 years . Fever (80.4 %), gastrointestinal (72.5 %), and respiratory symptoms (54.9 %) were the predominant symptoms . Cardiovascular abnormalities were the most frequent reported findings (82.4% , 42/51). The dermatological and conjunctival findings were reported in 39.2% and 35.3% of the patients, respectively . The increased level of inflammatory biomarkers was remarkable . Most of the patients were treated successfully with steroid and IVIG . Clinicians managing adult patients should keep in mind the development risk of MIS related with SARS-CoV-2 infection to perform necessary interventions properly without delay . IVIG and pulse steroid treatments are the effective options on clinical improvement.
Index: COVID-19, IVIG, MIS-A, Multisystem inflammatory syndrome, Pulse steroid